A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Huiping Li(Peking University), Bin Shao(Peking University), Shaorong Li(Capital Medical University), Guoying Xu(Shaoxing People's Hospital), Zhongsheng Tong(Institute of Oncology NN Petrov), Quchang Ouyang(Hunan Cancer Hospital), Yuting Wang(Jiangsu Hengrui Medicine (China))
Cited by 37
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer
|New England Journal of Medicine|2024|235
IL-1 Receptor Antagonist Prevents Apoptosis and Caspase-3 Activation after Spinal Cord Injury
|Journal of Neurotrauma|2001|181
Neurotoxicity of glutamate at the concentration released upon spinal cord injury
|Neuroscience|1999|168